1. How many patients have been treated for advanced (FIGO Stages III and IV) high-grade ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one?
2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
a. Paclitaxel in combination with a platinum-based compound
b. Platinum-based therapy alone (cisplatin or carboplatin)
c. Bevacizumab in combination with paclitaxel and carboplatin
d. Olaparib
e. Olaparib + Bevacizumab
f. Niraparib
g. Rucaparib
3. Of the ovarian cancer patients (any stage) treated over the last 3 months, how many patients:
a. Received HRD (homologous recombination deficiency) testing
b. Received BRCA testing
c. Tested HRD positive
d. Tested BRCA positive (BRCAm)
4. If data for HRD testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
5. If data for HRD and BRCA testing is available, please provide how many HRD positive-BRCA positive patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
